Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer
- 1 December 2006
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 116 (3), 275-284
- https://doi.org/10.1016/j.jconrel.2006.09.007
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibitionJournal of Controlled Release, 2006
- A novel stealth liposomal topotecan with amlodipine: Apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemiaJournal of Controlled Release, 2006
- A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle SystemJournal of Pharmacology and Experimental Therapeutics, 2006
- Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-AnalysisSeminars in Oncology, 2005
- Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cellsJournal of Controlled Release, 2005
- Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activityJournal of Controlled Release, 2005
- Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizersJournal of Pharmaceutical Sciences, 2004
- Can multidrug resistance mechanisms be modified?British Journal of Haematology, 2000
- Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinAnti-Cancer Drugs, 1999
- In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cellsJournal of Pharmaceutical Sciences, 1999